PDF(Pubmed)
Abstract：
The aim of the present study was to evaluate the diagnostic value of plasma human cystatin-S (CST4) in patients with digestive system malignant tumors. CST4 and tumor markers, such as α-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen (CA)199, CA125, CA153 and CA724, were detected in blood samples from 100 patients with a digestive system malignant tumor and 100 patients with benign digestive system diseases. The tumor markers AFP, CEA, CA199, CA125, CA153 and CA724 were detected using an electrochemiluminescence immunoassay, and CST4 levels were detected using a human CST4 ELISA kit. The results demonstrated that the sensitivities of AFP and CA153 (both 5.00%) were significantly lower than that of CST4 (38.00%) in the diagnosis of digestive system malignancy (P<0.001), and CA724 (18.00%) was also less sensitive than CST4 (P<0.05). The sensitivities of CA199 (26.00%), CEA (31.00%) and CA125 (25.00%) were similar to that of CST4 (P>0.05). There was no significant difference in the CEA, CA125, CA724 and CST4 specificities (P>0.05), which were 91.00, 95.00, 94.00 and 83.00%, respectively. The specificities of AFP (99.00%), CA199 (98.00%) and CA153 (100.00%) were significantly higher than that of CST4 (P<0.01). By constructing a receiver operating characteristic curve and comparing the area under the curve as well as sensitivity, the findings of the present study demonstrated that combining CST4 with AFP, CEA, CA199, CA125, CA153 and CA724 can significantly enhance the diagnostic sensitivity for malignancies of the digestive system. However, the introduction of CST4 into the traditional diagnostic groups (CEA + AFP, CA199 + CA125 + CA153 + CA724 and AFP + CEA + CA199 + CA125 + CA153 + CA724) resulted in an increased sensitivity and loss of specificity, thereby not offering significant advantages in terms of comprehensive diagnostic efficiency compared with the traditional diagnostic groups. In conclusion, CST4 detection may be a promising diagnostic tool. Nonetheless, the potential false positive results in tumor diagnosis should be taken into consideration when developing new diagnostic groups involving CST4.
摘要：
本研究的目的是评估血浆人胱抑素S（CST4）对消化系统恶性肿瘤的诊断价值。CST4和肿瘤标志物，如甲胎蛋白（AFP），癌胚抗原(CEA),在100例消化系统恶性肿瘤患者和100例良性消化系统疾病患者的血液样本中检测到碳水化合物抗原（CA）199，CA125，CA153和CA724。肿瘤标志物AFP，CEA,采用电化学发光免疫分析法检测CA199、CA125、CA153和CA724,和CST4水平使用人CST4ELISA试剂盒检测。结果表明，AFP和CA153诊断消化系统恶性肿瘤的敏感性（均为5.00％）明显低于CST4（38.00％）（P<0.001）。CA724(18.00%)的敏感性也低于CST4(P<0.05)。CA199的敏感性（26.00%），CEA(31.00%)和CA125(25.00%)与CST4相似(P>0.05)。CEA没有显著差异，CA125、CA724和CST4特异性（P>0.05），分别为91.00、95.00、94.00和83.00%，分别。AFP的特异性（99.00％），CA199(98.00%)和CA153(100.00%)显著高于CST4(P<0.01)。通过构建接收器工作特性曲线，并比较曲线下面积以及灵敏度，本研究的结果表明，将CST4与AFP相结合，CEA,CA199、CA125、CA153和CA724可显著提高消化系统恶性肿瘤的诊断敏感性。然而,将CST4引入传统诊断组(CEA+AFP，CA199+CA125+CA153+CA724和AFP+CEA+CA199+CA125+CA153+CA724)导致敏感性增加和特异性丧失,因此，与传统诊断组相比，在综合诊断效率方面没有提供显着优势。总之,CST4检测可能是一种有前途的诊断工具。尽管如此，在开发涉及CST4的新诊断组时,应考虑肿瘤诊断中潜在的假阳性结果.
